Journal Search Engine
Search Advanced Search Adode Reader(link)
Download PDF Export Citaion korean bibliography PMC previewer
ISSN : 2287-7991(Print)
ISSN : 2287-8009(Online)
Journal of the Preventive Veterinary Medicine Vol.44 No.3 pp.142-145
DOI : https://doi.org/10.13041/jpvm.2020.44.3.142

Production of recombinant new canine parvovirus 2a viral protein 2 in SF9 cells using a baculovirus expression system

Hyeonhae Choi#,Seyeon Park#,Yoon-Hee Lee,Ju-Yeon Lee,Jae Young Song,Seo Young Moon,Suyeong Yun,Soo-dong Cho,Jienny Lee,Bang-hun Hyun,In-Ohk Ouh
Viral Disease Division, Animal and Plant Quarantine Agency, Gimcheon 39660, Gyeongsangbuk-do, Republic of Korea
# These authors equally contributed.
Corresponding Author.
In-Ohk Ouh, Tel: +82-54-912-0812, Fax: +82-54-912-0812, E-mail: dvmoio@korea.kr

Abstract

Canine parvovirus (CPV) remains a leading infectious cause of death in canines, especially in young puppies. Though vaccination is being carried out regularly, immunization failures occur, and puppies may be exposed to infection. Virus-like particles (VLPs) act like a subunit vaccine, mimicking the structure of authentic viruses. Therefore, VLPs have the potential to be used as vaccine candidates. Since Viral Protein 2 (VP2), a major structural protein of CPV, is the crucial antigen for CPV, the purpose of this study was to produce a recombinant VP2 of new canine parvovirus-2a using the baculovirus expression system in SF9 insect cells. The results revealed that recombinant VP2 assembles to form VLPs with antigenic properties similar to those of natural CPV, the recombinant VLP can produce a hemagglutination assay (HA) titer (1:210) in SF9 cells. Expression of the recombinant 6-His-tagged VP2 in SF9 cells was confirmed by western blotting. These findings suggest that the recombinant VP2 expressed in this study could be used as an efficient subunit vaccine against CPV infection.

초록

Figure

Table